Amplia Therapeutics Ltd. has released a press release.
Preliminary Final Report and Annual Report YE 31 March 2026
Earlier from Amplia Therapeutics
- Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
- Amplia Launches First Stage of Pivotal Narmafotinib Trial
- Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
- Amplia and ANZGOG announce Ovarian Cancer Study